The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Renews GMP certifications for India and Malaysia sites
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
The state-of-the-art facility is equipped with best-in-class equipment and control systems
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Executes the first project for developing and manufacturing a novel anticancer mAb
Subscribe To Our Newsletter & Stay Updated
